Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?

Zacks2024-12-07

It has been about a month since the last earnings report for Pacira (PCRX). Shares have added about 5.5% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489251145?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","is_english":true,"pubTime":"2024-12-07 00:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489251145","market":"us","top_or_hot":-1,"title":"Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?","media":"Zacks","content":"<div>\n<p>It has been about a month since the last earnings report for Pacira (PCRX). Shares have added about 5.5% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pacira-pcrx-5-5-since-163123504.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPacira (PCRX) Up 5.5% Since Last Earnings Report: Can It Continue?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-07 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pacira-pcrx-5-5-since-163123504.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It has been about a month since the last earnings report for Pacira (PCRX). Shares have added about 5.5% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pacira-pcrx-5-5-since-163123504.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EXAS","symbol_name":"精密科学","start_time":0,"source_url":"https://finance.yahoo.com/news/pacira-pcrx-5-5-since-163123504.html","article_id":"2489251145","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489251145","pubTimestamp":1733502683,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"It has been about a month since the last earnings report for Pacira . Shares have added about 5.5% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Pacira due for a pullback?Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth. Pacira reported third-quarter 2024 adjusted earnings of 79 cents per share, which beat the Zacks Consensus Estimate of 72 cents. The company had reported adjusted earnings of 72 cents per share in the year-ago quarter.Total revenues amounted to $168.6 million, which increased 3% year over year but missed the Zacks Consensus Estimate of $169 million.Pacira’s top line comprises product sales and royalty revenues. The company recognizes product revenues from the sales of its three m","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EXAS":"精密科学","PCRX":"Pacira Pharmaceuticals"},"translate_title":"Pacira(PCRX)自上次收益报告以来上涨5.5%：还能继续吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCRX":1,"EXAS":0.9},"content_text":"It has been about a month since the last earnings report for Pacira (PCRX). Shares have added about 5.5% in that time frame, outperforming the S&P 500.\nWill the recent positive trend continue leading up to its next earnings release, or is Pacira due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. \nPacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth\nPacira reported third-quarter 2024 adjusted earnings of 79 cents per share, which beat the Zacks Consensus Estimate of 72 cents. The company had reported adjusted earnings of 72 cents per share in the year-ago quarter.\nTotal revenues amounted to $168.6 million, which increased 3% year over year but missed the Zacks Consensus Estimate of $169 million.\nPCRX’s Q3 Results in Detail\nPacira’s top line comprises product sales and royalty revenues. The company recognizes product revenues from the sales of its three marketed drugs — Exparel, Zilretta and iovera.\nExparel’s net product sales were $132 million, which increased 3% from the year-ago quarter figure. The reported figure beat the Zacks Consensus Estimate of $131.2 million and our model estimate of $130 million. Revenue growth from Exparel sales was partially offset by a shift in vial mix and contracted discounts.\nZilretta’s net product sales came in at $28.4 million, down slightly year over year. The reported figure missed the Zacks Consensus Estimate of $30.6 million as well as our model estimate of $30.1 million.\nNet product sales of iovera were $5.7 million, up 8% from the year-ago quarter. The figure missed the Zacks Consensus Estimate of $5.99 million as well as our model estimate of $5.9 million.\nRevenues generated from the sales of bupivacaine liposome injectable suspension to third-party licenses were pegged at $1.6 million, up significantly from the year-ago quarter’s figure. Royalty revenues amounted to $0.9 million in the reported quarter, up significantly year over year.\nResearch and development (R&D) expenses (excluding stock-based compensation) came in at $17.3 million, down 7% from the year-ago quarter due to lower product development and manufacturing capacity expansion costs as well as regulatory expenses in the reported quarter.\nSelling, general and administrative (SG&A) expenses (excluding stock-based compensation) of $65 million increased 10% year over year, largely due to litigation costs as well as a rise in investments made in commercial, medical and market access organizations.\nAs of Sept. 30, 2024, Pacira had cash, cash equivalents and available-for-sale investments of $453.8 million compared with $404.2 million as of June 30, 2024.\nPCRX Maintains 2024 Financial Guidance\nPacira reiterated its previously announced financial guidance for 2024. It expects total revenues in the band of $680-$705 million for the full year.\nThe company anticipates adjusted R&D expenses between $70 million and $80 million, while adjusted SG&A expenses are expected in the range of $245-$265 million.\nThe adjusted gross margin of the company is projected between 74% and 76% in 2024.\nHow Have Estimates Been Moving Since Then?\nIn the past month, investors have witnessed a downward trend in estimates revision.\nThe consensus estimate has shifted -5.66% due to these changes.\nVGM Scores\nCurrently, Pacira has a nice Growth Score of B, though it is lagging a bit on the Momentum Score front with a C. However, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.\nOverall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.\nOutlook\nEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Pacira has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.\nPerformance of an Industry Player\nPacira is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Exact Sciences (EXAS), a stock from the same industry, has gained 17.6%. The company reported its results for the quarter ended September 2024 more than a month ago.\nExact Sciences reported revenues of $708.66 million in the last reported quarter, representing a year-over-year change of +12.8%. EPS of -$0.21 for the same period compares with $0 a year ago.\nExact Sciences is expected to post a loss of $0.32 per share for the current quarter, representing a year-over-year change of -18.5%. Over the last 30 days, the Zacks Consensus Estimate has changed -200.3%.\nExact Sciences has a Zacks Rank #4 (Sell) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report\nExact Sciences Corporation (EXAS) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489251145"}